Relative Bioavailability of Two Formulations Containing Dapagliflozin 10 Mg Under Fed Condition in a Randomized Crossover Study in Healthy Caucasian Subjects
Abstract:The study aimed to evaluate the bioequivalence of a 10 mg dapagliflozin immediate release tablet, developed by Sun Pharmaceutical Industries, India, with the reference product Farxiga ® (AstraZeneca Pharmaceuticals LP, USA). The bioequivalence was assessed on 44 healthy Caucasian subjects under fed condition, of which 33 completed both study periods. The clinical trial was designed as an open label, randomized, single-dose, two-treatment, two-period, two-sequence, crossover study, with a wash-out period of 7 d… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.